Surrozen Inc. Common Stock (SRZN)

FairStock Score: 14/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable competitive advantages, consistent earnings, and a margin of safety. Surrozen fails most of these tests. It is a 44-employee biotechnology company trying to modulate the Wnt pathway for tissue repair; its lead candidates are still product candidates, not commercial products. Financial health is poor: trailing free cash flow is -$35.0M, FairStock's Altman Z-Score is -6.04, and its FairStock score is 14/100. It has lost money in each of the last four years, and the Peter Lynch category is none because of those losses. Revenue is tiny and erratic. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $5.0M and net income was $50.2M, but diluted EPS was -$0.41. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $5.0M and net income was -$127.5M. For FY2025, the period ended 2025-12-31, revenue was $3.5M and net income was -$242.0M. At the 2026-10-13 close of $23.51, FairStock's P/E is -0.60 and its FCF yield is -12.7%, so the $276.3M market cap is not supported by profits or cash generation. The jump from $983K in fiscal Q2 2025 to $5.0M in fiscal Q2 2026 is encouraging, but no earnings history and FairStock's ROCE of -25.39% mean I cannot call this a value investment. This is a pipeline speculation, not a Graham-style bargain. The price may reflect hope for clinical success, but the margin of safety is absent.

In plain English: Surrozen is a small biotech company working on medicines that help repair tissue. It has lost money in each of the last four years, brings in very little sales, and burns cash. Based on the numbers given, the stock price looks speculative and not cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer